目的 探討康艾注射液聯(lián)合mFOLFOX6方案治療晚期胃癌的臨床療效。方法 選取2022年4月—2024年3月在新疆醫(yī)科大學(xué)第一附屬醫(yī)院診斷為晚期胃癌且拒絕手術(shù)切除或無(wú)手術(shù)切除指征的82例患者，按隨機(jī)數(shù)字表法將患者分為對(duì)照組和治療組，每組41例。對(duì)照組給予mFOLFOX6方案，藥物包括奧沙利鉑注射液、注射用左亞葉酸鈣、氟尿嘧啶注射液。治療組在對(duì)照組基礎(chǔ)上靜脈滴注康艾注射液，60 mL加入250 mL生理鹽水后靜脈滴注，1次/d，持續(xù)治療2周，停藥1周。3周為1個(gè)治療周期，兩組在治療3個(gè)治療周期后分析療效。比較兩組治療效果、生活質(zhì)量、血清腫瘤標(biāo)志物、免疫指標(biāo)和不良反應(yīng)。結(jié)果 治療組的疾病控制率明顯高于對(duì)照組，組間差異顯著（95.12% vs 80.49%，P＜0.05）。治療后，兩組的KPS評(píng)分高于治療前（P＜0.05），且治療組的KPS評(píng)分較對(duì)照組更高（P＜0.05）。治療后，兩組的血清組織多肽特異性抗原（TPS）、癌胚抗原（CEA）、糖類(lèi)抗原724（CA724）水平低于治療前（P＜0.05）；治療組的血清TPS、CEA、CA724水平均比對(duì)照組低（P＜0.05）。治療后，兩組的PLR、NLR小于治療前（P＜0.05）；治療組的PLR、NLR小于對(duì)照組（P＜0.05）。治療組的口腔炎癥、惡心嘔吐、白細(xì)胞減少例數(shù)低于對(duì)照組（P＜0.05）。結(jié)論 康艾注射液聯(lián)合mFOLFOX6方案可提高晚期胃癌的疾病控制率，改善患者生活質(zhì)量，降低腫瘤標(biāo)志物水平，減輕炎癥反應(yīng)，降低不良反應(yīng)的發(fā)生。

Objective To investigate the clinical efficacy of Kangai Injection combined with mFOLFOX6 regimen in treatment of advanced gastric cancer. Methods 82 Patients with advanced gastric cancer who refused surgical resection or had no indications for surgical resection at The First Affiliated Hospital of Xinjiang Medical University from April 2022 to March 2024 were divided into control group and treatment group using a random number table method, with 41 patients in each group. The control group was treated with mFOLFOX6 regimen, which included Oxaliplatin Injection, Calcium Folinate for injection, and Fluorouracil Injection. Patients in treatment group were iv administered with Kangai Injection on the basis of the control group, with 60 mL added to 250 mL of physiological saline and intravenous infusion once daily. The treatment was continued for 2 weeks and stopped for 1 week. Three weeks was a course, and the clinical efficacies of the two groups were analyzed after three courses. The treatment efficacy, quality of life, serum tumor markers, immune indicators, and adverse reactions between two groups were compared. Results The disease control rate of the treatment group was significantly higher than that of the control group, with a significant difference between two groups (95.12% vs 80.49%, P < 0.05). The KPS scores of the two groups after treatment were higher than those before treatment (P < 0.05), and the KPS scores of the treatment group was higher than those in the control group (P < 0.05). The serum levels of TPS, CEA, and CA724 in both groups were lower than those before treatment (P < 0.05), and the serum levels of TPS, CEA, and CA724 levels in the treatment group were lower than those in the control group (P < 0.05). PLR and NLR of both groups after treatment were lower than those before treatment (P < 0.05), and the PLR and NLR of the treatment group were lower than those of the control group (P < 0.05). The oral inflammation, nausea and vomiting, and leukopenia in the treatment group were lower than those in the control group (P < 0.05). ConclusionThe combination of Kangai Injection and mFOLFOX6 regimen can improve the disease control rate of advanced gastric cancer, improve patients' quality of life, reduce tumor marker levels, alleviate inflammatory reactions, and reduce the occurrence of adverse reactions.

R979.1

新疆維吾爾自治區(qū)自然科學(xué)基金青年項(xiàng)目(2021D01C328)